<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117972</url>
  </required_header>
  <id_info>
    <org_study_id>API/2016/73</org_study_id>
    <nct_id>NCT03117972</nct_id>
  </id_info>
  <brief_title>Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels</brief_title>
  <acronym>CLavSyn</acronym>
  <official_title>Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan-1 Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death
      risk and strategy stratification are lacking. In this setting, a simple biological scoring
      system have recently been proposed, including LDH and CD138 binary status seric values,
      identifying one third of patients with worst prognostic.

      Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, Irinotecan and
      Bevacizumab, are beneficial for patients having a bad prognostic, defined by the BRAFV600E
      mutation, concerning 5-8% of first line mCRC.

      For the 30% of patients with LDH-CD138 elevated score, the purpose of CLavSyn phase II study
      is to compare the PFS of one intensified arm (FOLFOXIRI Bevacizumab) to one standard
      chemotherapy arm, in order to better discriminate treatment strategies, at metastatic
      diagnosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 4 years (3 years of inclusion and 12 months of follow up after the last patient included)</time_frame>
    <description>Delay from the date of randomization to the disease progression (RECIST) or death from any cause whichever occurs first</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A : FOLFOXIRI - bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: FOLFOX or FOLFIRI - bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>12 cycles</description>
    <arm_group_label>Arm A : FOLFOXIRI - bevacizumab</arm_group_label>
    <other_name>Irinotecan</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>12 cycles</description>
    <arm_group_label>Arm B: FOLFOX or FOLFIRI - bevacizumab</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>12 cycles</description>
    <arm_group_label>Arm B: FOLFOX or FOLFIRI - bevacizumab</arm_group_label>
    <other_name>Ironotecan</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>12 cycles</description>
    <arm_group_label>Arm A : FOLFOXIRI - bevacizumab</arm_group_label>
    <arm_group_label>Arm B: FOLFOX or FOLFIRI - bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2</intervention_name>
    <description>Maintenance chemotherapy</description>
    <arm_group_label>Arm A : FOLFOXIRI - bevacizumab</arm_group_label>
    <arm_group_label>Arm B: FOLFOX or FOLFIRI - bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Maintenance chemotherapy</description>
    <arm_group_label>Arm A : FOLFOXIRI - bevacizumab</arm_group_label>
    <arm_group_label>Arm B: FOLFOX or FOLFIRI - bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status ECOG-WHO 0 or 1

          -  Histologically proved metastatic colorectal adenocarcinoma, with non-resectable
             metastases

          -  Adequate hematological, hepatic, and renal functions

          -  Signed written informed consent

        Exclusion Criteria:

          -  Previous treatment (chemotherapy, targeted therapy, surgery) for metastatic disease

          -  History of autoimmune disease

          -  Acute infectious disease

          -  Known hypersensitivity grade 3-4 or contraindication to any of the study drugs

          -  Patient with any medical or psychiatric condition or disease which would make the
             patient inappropriate for entry into this study.

          -  Bevacizumab contraindication

          -  Brain metastases

          -  Other malignancy within the last 2 years, except for adequately treated carcinoma in
             situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited
             basal cell skin cancer.

          -  Pregnancy, breast-feeding or absence of adequate contraception for fertile patients

          -  Patient under guardianship, curator or under the protection of justice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine JARY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marine JARY, Dr</last_name>
    <phone>03 81 66 81 66</phone>
    <email>mjary@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe BORG, Pr</last_name>
    <phone>03 81 66 81 66</phone>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine JARY, PH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles BREYSACHER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariane Darut-Jouve, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Kim, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis-Marie Dourthe, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher Benabdelghani, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lecomte, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI de Haute-Saône</name>
      <address>
        <city>Vesoul</city>
        <zip>70014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Cleau, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score. Int J Cancer. 2016 Nov 15;139(10):2325-35. doi: 10.1002/ijc.30367. Epub 2016 Aug 13.</citation>
    <PMID>27472156</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Chemotherapy intensification</keyword>
  <keyword>Syndecan1</keyword>
  <keyword>LDH</keyword>
  <keyword>CD138</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

